Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (NCT06305754)
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study is that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to overall survival (OS).
Who can join: Review the eligibility criteria below.
Location: Kaiser Permanente - Oakland ( Site 0054) — Oakland, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (156 Sites)
Showing the first 25 of 156 sites.
- Kaiser Permanente - Oakland ( Site 0054) — Oakland, California
- Kaiser Permanente - Roseville ( Site 0055) — Roseville, California
- Kaiser Permanente - San Francisco ( Site 0056) — San Francisco, California
- Kaiser Permanente - Santa Clara ( Site 0057) — Santa Clara, California
- Kaiser Permanente-Kaiser Permanente ( Site 0036) — Vallejo, California
- Kaiser Permanente - Walnut Creek ( Site 0058) — Walnut Creek, California
- Mid Florida Hematology and Oncology Center ( Site 0005) — Orange City, Florida
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003) — Marietta, Georgia
- University of Michigan ( Site 0009) — Ann Arbor, Michigan
- Cox Medical Center North - Cox Medical Center/ Hematology/Medical Oncology ( Site 0051) — Springfield, Missouri
- Astera Cancer Care ( Site 0032) — East Brunswick, New Jersey
- Stony Brook University-Cancer Center ( Site 0038) — Stony Brook, New York
- Sanford Fargo Medical Center ( Site 0028) — Fargo, North Dakota
- Sanford Cancer Center ( Site 0024) — Sioux Falls, South Dakota
- John Peter Smith Hospital ( Site 0065) — Fort Worth, Texas
- University of Texas MD Anderson ( Site 0063) — Houston, Texas
- Millennium Research & Clinical Development ( Site 0035) — Houston, Texas
- Clinica Adventista Belgrano-Oncology ( Site 0315) — Caba., Buenos Aires
- Instituto Alexander Fleming ( Site 0307) — Ciudad Autónoma de Buenos Aires, Buenos Aires
- Hospital Británico de Buenos Aires-Oncology ( Site 0304) — Buenos Aires, Buenos Aires F.D.
- Centro Privado de RMI Río Cuarto S.A. II ( Site 0310) — Río Cuarto, Córdoba Province
- Instituto de Oncología de Rosario ( Site 0301) — Rosario, Santa Fe Province
- Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0303) — La Rioja,
- Cross Cancer Institute ( Site 0201) — Edmonton, Alberta
- Waterloo Regional Health Network (WRHN) ( Site 0207) — Kitchener, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-small Cell Lung Cancer (NSCLC)
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama
Explore by condition: All Non-small Cell Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.